Tempest Therapeutics (TPST) Accounts Payables (2011 - 2026)
Tempest Therapeutics (TPST) posted Accounts Payables of $1.0 million for Q4 2025, up 12.58% sequentially from $922000.0 in Q3 2025, and down 57.63% YoY from $2.4 million in Q4 2024.
Tempest Therapeutics (TPST) Accounts Payables (2011 - 2026) Analysis & Trends
Tempest Therapeutics has reported Accounts Payables for 15 years, with the latest figure at $1.0 million in Q4 2025.
- Quarterly Accounts Payables fell 57.63% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 million (down 57.63% YoY) and the FY2025 annual result came in at $1.0 million, down 57.63% from the prior year.
- Accounts Payables climbed to $1.0 million in Q4 2025 per TPST's latest filing, from $922000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $6.7 million in Q2 2021 and troughed at $684000.0 in Q1 2022.
- A 5-year average of $1.7 million and a median of $1.1 million in 2022 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2021 and 2022: Accounts Payables soared 399.63% in 2021, then tumbled 78.37% in 2022.
- Over 5 years, Accounts Payables stood at $991000.0 in 2021, then rose by 11.81% to $1.1 million in 2022, then slipped by 23.74% to $845000.0 in 2023, then jumped by 189.94% to $2.4 million in 2024, then sank by 57.63% to $1.0 million in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.0 million, $922000.0, and $4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 35.57 Mn |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - | 2.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.00 Mn |
| Dec 31, 2025 | 1.04 Mn |
| Sep 30, 2025 | 922,000.00 |
| Jun 30, 2025 | 4.72 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Dec 31, 2024 | 2.45 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.36 Mn |
| Mar 31, 2024 | 1.05 Mn |
| Dec 31, 2023 | 845,000.00 |
| Sep 30, 2023 | 1.14 Mn |
| Jun 30, 2023 | 868,000.00 |
| Mar 31, 2023 | 1.16 Mn |
| Dec 31, 2022 | 1.11 Mn |
| Sep 30, 2022 | 925,000.00 |
| Jun 30, 2022 | 1.45 Mn |
| Mar 31, 2022 | 684,000.00 |
| Dec 31, 2021 | 991,000.00 |
| Sep 30, 2021 | 2.38 Mn |
| Jun 30, 2021 | 6.70 Mn |